Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Lung Cancer

  Free Subscription

Articles published in J Clin Oncol

Retrieve available abstracts of 98 articles:
HTML format

Single Articles

    August 2022
  1. LIGIBEL JA, Bohlke K, May AM, Clinton SK, et al
    Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline.
    J Clin Oncol. 2022;40:2491-2507.
    PubMed     Abstract available

    July 2022
  2. SINGH N, Temin S, Baker S Jr, Blanchard E, et al
    Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
    J Clin Oncol. 2022 Jul 11:JCO2200825. doi: 10.1200/JCO.22.00825.
    PubMed     Abstract available

  3. SINGH N, Temin S, Baker S Jr, Blanchard E, et al
    Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline.
    J Clin Oncol. 2022 Jul 11:JCO2200824. doi: 10.1200/JCO.22.00824.
    PubMed     Abstract available

    June 2022
  4. MACK PC, Hirsch FR, Bunn PA, Minna JD, et al
    Longitudinal COVID-19 Vaccination-Induced Antibody Responses and Omicron Neutralization in Patients With Lung Cancer.
    J Clin Oncol. 2022 Jun 27:JCO2201136. doi: 10.1200/JCO.22.01136.

  5. VALANPARAMBIL RM, Carlisle J, Linderman SL, Akthar A, et al
    Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
    J Clin Oncol. 2022 Jun 27:JCO2102986. doi: 10.1200/JCO.21.02986.
    PubMed     Abstract available

    Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jun 20:JCO2200827. doi: 10.1200/JCO.22.00827.

  7. PASSARO A, Attili I, de Marinis F
    Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jun 17:JCO2200873. doi: 10.1200/JCO.22.00873.
    PubMed     Abstract available

  8. AGGARWAL C, Gyawali B
    Aumolertinib in EGFR-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease Access?
    J Clin Oncol. 2022 Jun 9:JCO2200903. doi: 10.1200/JCO.22.00903.

  9. PEROL M, Swalduz A
    Lorlatinib in Frontline Therapy for ALK+ Advanced Non-Small-Cell Lung Cancer: Still a Matter of Debate?
    J Clin Oncol. 2022 Jun 9:JCO2200859. doi: 10.1200/JCO.22.00859.

  10. RECKAMP KL, Redman MW, Dragnev KH, Minichiello K, et al
    Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.
    J Clin Oncol. 2022 Jun 3:JCO2200912. doi: 10.1200/JCO.22.00912.
    PubMed     Abstract available

    May 2022
  11. SOLOMON BJ, Bauer TM, Ignatius Ou SH, Liu G, et al
    Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.
    J Clin Oncol. 2022 May 23:JCO2102278. doi: 10.1200/JCO.21.02278.
    PubMed     Abstract available

  12. RIVERA MP, Cupertino P, Henderson LM
    Complementary Approaches to Lung Cancer Detection in High-Risk Populations.
    J Clin Oncol. 2022 May 23:JCO2200494. doi: 10.1200/JCO.22.00494.

  13. LU S, Dong X, Jian H, Chen J, et al
    AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
    J Clin Oncol. 2022 May 17:JCO2102641. doi: 10.1200/JCO.21.02641.
    PubMed     Abstract available

  14. PROVENCIO M, Serna-Blasco R, Nadal E, Insa A, et al
    Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).
    J Clin Oncol. 2022 May 16:JCO2102660. doi: 10.1200/JCO.21.02660.
    PubMed     Abstract available

  15. FALLET V, Sanchis-Borja M, Benusiglio PR, Cadranel J, et al
    Do Female BRCA2 Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?
    J Clin Oncol. 2022 May 12:JCO2200488. doi: 10.1200/JCO.22.00488.

    April 2022
  16. HERBST RS, Majem M, Barlesi F, Carcereny E, et al
    COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Apr 22:JCO2200227. doi: 10.1200/JCO.22.00227.
    PubMed     Abstract available

    Lung Cancer Disparities Outcomes: The Urgent Need for Narrowing Care Gaps.
    J Clin Oncol. 2022 Apr 15:JCO2200321. doi: 10.1200/JCO.22.00321.

    March 2022
  18. PARK S, Ock CY, Kim H, Pereira S, et al
    Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Mar 10:JCO2102010. doi: 10.1200/JCO.21.02010.
    PubMed     Abstract available

  19. OSAROGIAGBON RU, Liao W, Faris NR, Meadows-Taylor M, et al
    Lung Cancer Diagnosed Through Screening, Lung Nodule, and Neither Program: A Prospective Observational Study of the Detecting Early Lung Cancer (DELUGE) in the Mississippi Delta Cohort.
    J Clin Oncol. 2022 Mar 8:JCO2102496. doi: 10.1200/JCO.21.02496.
    PubMed     Abstract available

  20. PUJOL JL
    Durvalumab Induces Sustained Survival Benefit After Concurrent Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Mar 3:JCO2200204. doi: 10.1200/JCO.22.00204.

    February 2022
  21. TSAO AS, Pass HI, Rimner A, Mansfield AS, et al
    New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
    J Clin Oncol. 2022;40:681-692.
    PubMed     Abstract available

  22. STINCHCOMBE TE, Bradley JD
    Thoracic Oncology: Current Standard Therapy and Future Developments.
    J Clin Oncol. 2022;40:527-529.

  23. PISTERS K, Kris MG, Gaspar LE, Ismaila N, et al
    Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Feb 15:JCO2200051. doi: 10.1200/JCO.22.00051.
    PubMed     Abstract available

  24. CHARLOT M, Stein JN, Damone E, Wood I, et al
    Effect of an Antiracism Intervention on Racial Disparities in Time to Lung Cancer Surgery.
    J Clin Oncol. 2022 Feb 14:JCO2101745. doi: 10.1200/JCO.21.01745.
    PubMed     Abstract available

  25. PIRES DA SILVA I, Ahmed T, McQuade JL, Nebhan CA, et al
    Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
    J Clin Oncol. 2022 Feb 10:JCO2101701. doi: 10.1200/JCO.21.01701.
    PubMed     Abstract available

  26. SPIGEL DR, Faivre-Finn C, Gray JE, Vicente D, et al
    Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Feb 2:JCO2101308. doi: 10.1200/JCO.21.01308.
    PubMed     Abstract available

    Who Is MB and What Does She Want?
    J Clin Oncol. 2022;40:427-429.

    January 2022
  28. MAZIERES J, Lafitte C, Ricordel C, Greillier L, et al
    Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial.
    J Clin Oncol. 2022 Jan 24:JCO2101455. doi: 10.1200/JCO.21.01455.
    PubMed     Abstract available

  29. COOPER AJ, Gainor JF
    Human Epidermal Growth Factor Receptor 2-Mutant Non-Small-Cell Lung Cancer: Continued Progress But Challenges Remain.
    J Clin Oncol. 2022 Jan 24:JCO2102550. doi: 10.1200/JCO.21.02550.

  30. FAHRMANN JF, Marsh T, Irajizad E, Patel N, et al
    Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.
    J Clin Oncol. 2022 Jan 7:JCO2101460. doi: 10.1200/JCO.21.01460.
    PubMed     Abstract available

  31. DAI W, Feng W, Zhang Y, Wang XS, et al
    Patient-Reported Outcome-Based Symptom Management Versus Usual Care After Lung Cancer Surgery: A Multicenter Randomized Controlled Trial.
    J Clin Oncol. 2022 Jan 7:JCO2101344. doi: 10.1200/JCO.21.01344.
    PubMed     Abstract available

  32. PASSARO A, Brahmer J, Antonia S, Mok T, et al
    Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies.
    J Clin Oncol. 2022 Jan 5:JCO2101845. doi: 10.1200/JCO.21.01845.
    PubMed     Abstract available

  33. CHAFT JE, Shyr Y, Sepesi B, Forde PM, et al
    Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101589. doi: 10.1200/JCO.21.01589.
    PubMed     Abstract available

  34. DONINGTON J, Schumacher L, Yanagawa J
    Surgical Issues for Operable Early-Stage Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101592. doi: 10.1200/JCO.21.01592.
    PubMed     Abstract available

  35. TSUI DCC, Camidge DR, Rusthoven CG
    Managing Central Nervous System Spread of Lung Cancer: The State of the Art.
    J Clin Oncol. 2022 Jan 5:JCO2101715. doi: 10.1200/JCO.21.01715.
    PubMed     Abstract available

  36. PELLINI B, Chaudhuri AA
    Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.
    J Clin Oncol. 2022 Jan 5:JCO2101929. doi: 10.1200/JCO.21.01929.
    PubMed     Abstract available

  37. BOGART JA, Waqar SN, Mix MD
    Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101639. doi: 10.1200/JCO.21.01639.
    PubMed     Abstract available

  38. TEMEL JS, Petrillo LA, Greer JA
    Patient-Centered Palliative Care for Patients With Advanced Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101710. doi: 10.1200/JCO.21.01710.
    PubMed     Abstract available

  39. HIGGINS KA, Puri S, Gray JE
    Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101707. doi: 10.1200/JCO.21.01707.
    PubMed     Abstract available

  40. LEVY A, Mercier O, Le Pechoux C
    Indications and Parameters Around Postoperative Radiation Therapy for Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101774. doi: 10.1200/JCO.21.01774.
    PubMed     Abstract available

  41. ZUGAZAGOITIA J, Paz-Ares L
    Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options.
    J Clin Oncol. 2022 Jan 5:JCO2101881. doi: 10.1200/JCO.21.01881.
    PubMed     Abstract available

  42. DALY ME
    Inoperable Early-Stage Non-Small-Cell Lung Cancer: Stereotactic Ablative Radiotherapy and Rationale for Systemic Therapy.
    J Clin Oncol. 2022 Jan 5:JCO2101611. doi: 10.1200/JCO.21.01611.
    PubMed     Abstract available

  43. RECK M, Remon J, Hellmann MD
    First-Line Immunotherapy for Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101497. doi: 10.1200/JCO.21.01497.
    PubMed     Abstract available

  44. TAN AC, Tan DSW
    Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
    J Clin Oncol. 2022 Jan 5:JCO2101626. doi: 10.1200/JCO.21.01626.
    PubMed     Abstract available

  45. JASPER K, Stiles B, McDonald F, Palma DA, et al
    Practical Management of Oligometastatic Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2022 Jan 5:JCO2101719. doi: 10.1200/JCO.21.01719.
    PubMed     Abstract available

    December 2021
  46. DALY ME, Singh N, Ismaila N, Antonoff MB, et al
    Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.
    J Clin Oncol. 2021 Dec 22:JCO2102528. doi: 10.1200/JCO.21.02528.
    PubMed     Abstract available

    November 2021
  47. LE X, Cornelissen R, Garassino M, Clarke JM, et al
    Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.
    J Clin Oncol. 2021 Nov 29:JCO2101323. doi: 10.1200/JCO.21.01323.
    PubMed     Abstract available

  48. DEVARAKONDA S, Li Y, Martins Rodrigues F, Sankararaman S, et al
    Genomic Profiling of Lung Adenocarcinoma in Never-Smokers.
    J Clin Oncol. 2021;39:3747-3758.
    PubMed     Abstract available

  49. LIU SY, Zhang JT, Wu YL
    What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Nov 18:JCO2102443. doi: 10.1200/JCO.21.02443.

  50. TADA H, Mitsudomi T, Misumi T, Sugio K, et al
    Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT).
    J Clin Oncol. 2021 Nov 2:JCO2101729. doi: 10.1200/JCO.21.01729.
    PubMed     Abstract available

  51. SOULIERES D, Gelmon KA
    Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand?
    J Clin Oncol. 2021;39:3427-3429.

    October 2021
  52. BROWN PD, Parsons MW, Rusthoven CG, Gondi V, et al
    Hippocampal Avoidance Prophylactic Cranial Irradiation: A New Standard of Care?
    J Clin Oncol. 2021;39:3093-3096.

    September 2021
  53. ELAMIN YY, Robichaux JP, Carter BW, Altan M, et al
    Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.
    J Clin Oncol. 2021 Sep 22:JCO2101113. doi: 10.1200/JCO.21.01113.
    PubMed     Abstract available

  54. DRILON A, Duruisseaux M, Han JY, Ito M, et al
    Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.
    J Clin Oncol. 2021;39:2791-2802.
    PubMed     Abstract available

    August 2021
  55. RAMALINGAM SS, Novello S, Guclu SZ, Bentsion D, et al
    Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.
    J Clin Oncol. 2021 Aug 26:JCO2003318. doi: 10.1200/JCO.20.03318.
    PubMed     Abstract available

  56. RODRIGUEZ DE DIOS N, Counago F, Murcia-Mejia M, Rico-Oses M, et al
    Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study.
    J Clin Oncol. 2021 Aug 11:JCO2100639. doi: 10.1200/JCO.21.00639.
    PubMed     Abstract available

  57. PARK K, Haura EB, Leighl NB, Mitchell P, et al
    Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
    J Clin Oncol. 2021 Aug 2:JCO2100662. doi: 10.1200/JCO.21.00662.
    PubMed     Abstract available

  58. SHU CA, Cascone T
    What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Aug 2:JCO2101446. doi: 10.1200/JCO.21.01446.

    July 2021
  59. ROTHSCHILD SI, Zippelius A, Eboulet EI, Savic Prince S, et al
    SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
    J Clin Oncol. 2021 Jul 12:JCO2100276. doi: 10.1200/JCO.21.00276.
    PubMed     Abstract available

    June 2021
  60. REMON J, Hendriks LEL, Besse B
    Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Jun 8:JCO2100760. doi: 10.1200/JCO.21.00760.

  61. PASSIGLIA F, Cinquini M, Bertolaccini L, Del Re M, et al
    Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2021 Jun 2:JCO2002574. doi: 10.1200/JCO.20.02574.
    PubMed     Abstract available

    May 2021
  62. GILLESSEN S, Sauve N, Collette L, Daugaard G, et al
    Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
    J Clin Oncol. 2021;39:1563-1574.
    PubMed     Abstract available

    April 2021
  63. RECK M, Rodriguez-Abreu D, Robinson AG, Hui R, et al
    Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50.
    J Clin Oncol. 2021 Apr 19:JCO2100174. doi: 10.1200/JCO.21.00174.
    PubMed     Abstract available

    March 2021
  64. OWONIKOKO TK, Park K, Govindan R, Ready N, et al
    Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
    J Clin Oncol. 2021 Mar 8:JCO2002212. doi: 10.1200/JCO.20.02212.
    PubMed     Abstract available

  65. DERKS JL, Speel EM, Dingemans AC
    Adjuvant Chemotherapy in Patients With Stage I-IIIA Large-Cell Neuroendocrine Carcinoma: Should a Different Approach Be Applied Than for Small-Cell Lung Cancer?
    J Clin Oncol. 2021 Mar 4:JCO2003598. doi: 10.1200/JCO.20.03598.

  66. DZIADZIUSZKO R, Krebs MG, De Braud F, Siena S, et al
    Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Mar 1:JCO2003025. doi: 10.1200/JCO.20.03025.
    PubMed     Abstract available

  67. WAQAR SN, Govindan R
    Adjuvant Therapy With EGFR Tyrosine Kinase Inhibitors: Tempering Great Expectations With Realism.
    J Clin Oncol. 2021;39:697-700.

  68. ZHONG WZ, Wang Q, Mao WM, Xu ST, et al
    Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
    J Clin Oncol. 2021;39:713-722.
    PubMed     Abstract available

    February 2021
  69. HANNA NH, Robinson AG, Temin S, Baker S Jr, et al
    Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
    J Clin Oncol. 2021 Feb 16:JCO2003570. doi: 10.1200/JCO.20.03570.
    PubMed     Abstract available

  70. EWER MS, Tekumalla SH, Walding A, Atuah KN, et al
    Cardiac Safety of Osimertinib: A Review of Data.
    J Clin Oncol. 2021;39:328-337.
    PubMed     Abstract available

    January 2021
  71. BOYER M, Sendur MAN, Rodriguez-Abreu D, Park K, et al
    Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
    J Clin Oncol. 2021 Jan 29:JCO2003579. doi: 10.1200/JCO.20.03579.
    PubMed     Abstract available

  72. DALY ME, Ismaila N, Decker RH, Higgins K, et al
    Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline.
    J Clin Oncol. 2021 Jan 27:JCO2003364. doi: 10.1200/JCO.20.03364.
    PubMed     Abstract available

  73. GYAWALI B, West HJ
    Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.
    J Clin Oncol. 2021;39:175-177.

  74. BORGHAEI H, Gettinger S, Vokes EE, Chow LQM, et al
    Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2021 Jan 15:JCO2001605. doi: 10.1200/JCO.20.01605.
    PubMed     Abstract available

  75. LIU SV, Reck M, Mansfield AS, Mok T, et al
    Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
    J Clin Oncol. 2021 Jan 13:JCO2001055. doi: 10.1200/JCO.20.01055.
    PubMed     Abstract available

    December 2020
  76. KENMOTSU H, Niho S, Tsuboi M, Wakabayashi M, et al
    Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206.
    J Clin Oncol. 2020;38:4292-4301.
    PubMed     Abstract available

  77. BEKELMAN JE, Gupta A, Fishman E, Debono D, et al
    Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending.
    J Clin Oncol. 2020;38:4055-4063.
    PubMed     Abstract available

    November 2020
  78. GARASSINO MC, Besse B, Torri V
    To Continue or Not to Continue? That Is the Question.
    J Clin Oncol. 2020;38:3830-3832.

  79. LAU YM, Mok TSK
    The More, The Better?
    J Clin Oncol. 2020;38:3581-3583.

  80. ANG E
    Four Women, One Evening.
    J Clin Oncol. 2020;38:3716-3718.

    October 2020
  81. BURNS TF, Borghaei H, Ramalingam SS, Mok TS, et al
    Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.
    J Clin Oncol. 2020 Oct 26:JCO2000744. doi: 10.1200/JCO.20.00744.

    Volume-Based Care Regionalization: Pitfalls and Challenges.
    J Clin Oncol. 2020;38:3465-3467.

  83. GOLDBERG SB, Redman MW, Lilenbaum R, Politi K, et al
    Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.
    J Clin Oncol. 2020 Oct 6:JCO2001149. doi: 10.1200/JCO.20.01149.
    PubMed     Abstract available

    September 2020
  84. WATERHOUSE DM, Garon EB, Chandler J, McCleod M, et al
    Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
    J Clin Oncol. 2020 Sep 10:JCO2000131. doi: 10.1200/JCO.20.00131.
    PubMed     Abstract available

    August 2020
  85. ZHOU C, Li X, Wang Q, Gao G, et al
    Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study.
    J Clin Oncol. 2020;38:2753-2761.
    PubMed     Abstract available

  86. CAMIDGE DR, Kim HR, Ahn MJ, Yang JCH, et al
    Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
    J Clin Oncol. 2020 Aug 11:JCO2000505. doi: 10.1200/JCO.20.00505.
    PubMed     Abstract available

  87. RUSTHOVEN CG, Camidge DR, Robin TP, Brown PD, et al
    Radiosurgery for Small-Cell Brain Metastases: Challenging the Last Bastion of Preferential Whole-Brain Radiotherapy Delivery.
    J Clin Oncol. 2020 Aug 10:JCO2001823. doi: 10.1200/JCO.20.01823.

  88. FARJAH F, Grau-Sepulveda MV, Gaissert H, Block M, et al
    Volume Pledge is Not Associated with Better Short-Term Outcomes After Lung Cancer Resection.
    J Clin Oncol. 2020 Aug 7:JCO2000329. doi: 10.1200/JCO.20.00329.
    PubMed     Abstract available

    May 2020
  89. RUDIN CM, Awad MM, Navarro A, Gottfried M, et al
    Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
    J Clin Oncol. 2020 May 29:JCO2000793. doi: 10.1200/JCO.20.00793.
    PubMed     Abstract available

  90. RECK M, Wehler T, Orlandi F, Nogami N, et al
    Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2020 May 27:JCO1903158. doi: 10.1200/JCO.19.03158.
    PubMed     Abstract available

  91. KENMOTSU H, Yamamoto N, Yamanaka T, Yoshiya K, et al
    Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2020 May 14:JCO1902674. doi: 10.1200/JCO.19.02674.
    PubMed     Abstract available

  92. LEVY EB, Fiel MI, Hamilton SR, Kleiner DE, et al
    State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach.
    J Clin Oncol. 2020;38:1633-1640.
    PubMed     Abstract available

    March 2020
  93. NORONHA V, Patil VM, Joshi A, Menon N, et al
    Reply to T. Tanaka et al and F. Liang.
    J Clin Oncol. 2020;38:844-846.

  94. LIANG F
    Contradiction Between Stated Statistical Analysis Method and Displayed Survival Curves.
    J Clin Oncol. 2020;38:844.

  95. RAMALINGAM SS, Dahlberg SE
    Reply to N. Hanna et al and L. Xie et al.
    J Clin Oncol. 2020;38:771-772.

  96. HANNA N, Jalal S
    The Case for Maintenance Pemetrexed Plus Bevacizumab.
    J Clin Oncol. 2020;38:770-771.

    January 2020
  97. WU YL, Zhong WZ, Yan HH
    Reply to A. Tateishi et al.
    J Clin Oncol. 2020;38:286-287.

  98. TATEISHI A, Ishiki H, Kubo E, Satomi E, et al
    EMERGING-CTONG 1103: For Achieving High-Quality Evidence in a Randomized Phase II Trial.
    J Clin Oncol. 2020;38:285-286.

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.